Research advances from the National Institutes of Health (NIH) Intramural Research Program (IRP) often make headlines. Read the news releases that describe our most recent findings:
Whether you’re shedding pounds with the help of effective new medicines, slimming down after weight loss surgery or cutting calories and adding exercise, there will come a day when the numbers on the scale stop going down, and you hit the dreaded weight loss plateau.
In a recent study, Kevin Hall, a researcher at the National Institutes of Health who specializes in measuring metabolism and weight change, looked at when weight loss typically stops depending on the method people were using todrop pounds. He broke down the plateau into mathematical models using data from high-quality clinical trials of different ways to lose weight to understand why people stop losing when they do. The study published Monday in the journal Obesity.
The Clinical Center at the National Institutes of Health is investigating the potential use of a new generation of a computerized tomography (CT) scanner, called a photon-counting detector CT scanner, in a clinical setting. The prototype technology is expected to replicate the image quality of conventional CT scanning, but may also provide health care specialists with an enhanced look inside the body through multi-energy imaging. Patients could receive a minimum amount of radiation, while the maximal amount of information needed would be delivered to health care providers.
Over the next five years, David Bluemke, M.D., Ph.D., chief of the Department of Radiology and Imaging Sciences, and his team will continue to develop scan protocols and image processing algorithms, which could improve screening, imaging, and treatment planning for health conditions like cancer and cardiovascular disease.
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer. They also found evidence that this methylation signature may be present in many more types of cancer. The specific signature results from a chemical modification of DNA called methylation, which can control the expression of genes like a dimmer on a light switch. Higher amounts of DNA methylation (hypermethylation), like that found by the researchers in some tumor DNA, decreases a gene's activity. Based on this advance, the researchers hope to spur development of a blood test that can be used to diagnose a variety of cancers at early stages, when treatments can be most effective.
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Increasing the level of a naturally-produced protein, called tristetraprolin (TTP), significantly reduced or protected mice from inflammation, according to researchers at the National Institutes of Health. The results suggest that pharmaceutical compounds or other therapeutic methods that produce elevated levels of TTP in humans may offer an effective treatment for some inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis. The report appeared online Feb. 1 in the Proceedings of the National Academy of Sciences.
Scientists at the National Institutes of Health have identified a genetic mutation responsible for a rare form of inherited hives induced by vibration, also known as vibratory urticaria. Running, hand clapping, towel drying or even taking a bumpy bus ride can cause temporary skin rashes in people with this rare disorder. By studying affected families, researchers discovered how vibration promotes the release of inflammatory chemicals from the immune system’s mast cells, causing hives and other allergic symptoms.
Their findings, published online in the New England Journal of Medicine on Feb. 3, suggest that people with this form of vibratory urticaria experience an exaggerated version of a normal cellular response to vibration. The study was led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and the National Human Genome Research Institute (NHGRI), both part of NIH.
An international consortium of scientists has identified a stretch of chromosome that is associated with responsiveness to the mood-stabilizing medication lithium among patients with bipolar disorder. While the finding won’t have an immediate clinical application, it is a groundbreaking demonstration of the potential for identifying genetic information that can be used to inform personalized treatment decisions, even in genetically complex disorders. The genes identified are also an avenue for understanding the biology of the lithium response.
People with bipolar disorder experience marked, often extreme shifts in mood and energy. The disorder affects an estimated 2.6 percent of Americans. The mood swings can severely disrupt a person’s ability to function normally; as many as 15 percent of those affected die by suicide. Lithium is a mood stabilizing medication that is a mainstay of treatment. For some patients, it is very effective, virtually eliminating the symptoms. However, about a third of patients respond incompletely, and another third not at all.
A new study shows that it is possible to use an imaging technique called cryo-electron microscopy (cryo-EM) to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells. The cryo-EM images also helped the researchers establish, at atomic resolution, the sequence of structural changes that normally occur in the protein, p97, an enzyme critical for protein regulation that is thought to be a novel anti-cancer target.
The study appeared online January 28, 2016, in Science. Sriram Subramaniam, Ph.D., of the National Cancer Institute’s (NCI) Center for Cancer Research, led the research. NCI is part of the National Institutes of Health.
Frequent measurement of blood flow changes could improve the ability of health care providers to diagnose and treat patients with vascular conditions, such as those associated with diabetes and high blood pressure. A U.S.-Chinese team that included researchers from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Heart, Lung, and Blood Institute, both parts of the National Institutes of Health, conducted a pilot study showing that an ultrathin, skin-conforming sensor—resembling a peel-away tattoo—provides non-invasive, precise, and continuous monitoring of circulation, including blood flow within the smallest vessels.
In a study published in the Oct. 30, 2015 issue of Science Advances, the researchers showed that the sensor can measure blood flow in both large and micro-sized blood vessels near the skin’s surface. They also provided details about the design and operation of the device. The researchers assessed the sensor’s performance under various conditions, showing that the technology could be used for continuous blood-flow monitoring during daily activities and in a variety of clinical research and health care settings.
Driving under the influence of drugs is a major public safety issue, and marijuana is the illicit drug most commonly found in the blood of drivers. There is an ongoing challenge to develop valid tests of driver intoxication with appropriate legal limits for blood concentration of THC, a primary ingredient in marijuana, or its metabolites. Due to the chemical profile of THC, its concentration in the blood diminishes rapidly after smoking, but impairment does not diminish as rapidly, rendering THC concentration in blood samples collected after driving an imperfect means for the person’s level of impairment while driving.
Researchers at the National Institute on Drug Abuse’s (NIDA) Intramural Research Program and the University of Iowa tested the blood THC concentrations of adults before, during, and after driving in the National Advanced Driving Simulator, to evaluate how changes in THC concentration may affect the interpretation of toxicology results. Results showed that even though blood THC concentrations while driving were at levels that affected driving ability, they had decreased to under commonly used impairment testing thresholds after a few hours. Consumption of alcohol, along with marijuana, did not significantly affect the blood results for marijuana.
More than 1 in 20 (nearly 3.3 million) children between the ages of 3 and 17 have a dizziness or balance problem, according to an analysis of the first large-scale, nationally representative survey of these problems in U.S. children. Prevalence increases with age, with 7.5 percent of children ages 15-17 and 6.0 percent of children ages 12-14 having any dizziness or balance problem, compared with 3.6 percent of children ages 6-8 and 4.1 percent of children ages 3-5. The research was led by investigators at the National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health.
Researchers found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent, respectively. In addition, non-Hispanic white children have an increased prevalence of dizziness and balance problems (6.1 percent) compared with Hispanic (4.6 percent) and non-Hispanic black (4.3 percent) children. The findings were published online January 27 in The Journal of Pediatrics.
Investigational Vaccine to Prevent “Breakbone Fever” Developed at NIH
A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The Butantan Institute, a non-profit producer of immunobiologic products for Brazil, licensed the NIAID dengue vaccine technology and is sponsoring the placebo-controlled, multi-center Phase 3 trial using test vaccine produced in Sao Paulo.
A female Aedes aegypti mosquito ingesting a blood meal. Credit: CDC
